Jeffrey E. Lancet - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Jeffrey E. Lancet's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Jeffrey E. Lancet
Verified
Contributor, Leukemia
Tampa
Beats
Health/wellness, pregnancy technology, parenting women in STEM, teens special needs, college
Music, Sports
Content
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients
By Christopher Dukes, Jeffrey E. Lancet, Barbara J. Kuter, Marine Potez| MDPI@ All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
By Qianxing Mo, Seongseok Yun, David A Sallman, Jeffrey E. Lancet| Nature Verified Dear Editor,AML is a heterogenous disease characterized by distinct clinical courses and prognoses based on genomic, epigenomic and transcriptomic profiles [1, 2]. Therefore, molecular classification and risk stratification are essential for clinical decision. Although cytogenetics is one of the most powerful prognostic indicators in AML, more than 50% of AML patients have normal karyotypes.
Neutralizing Antibody Response following a Third Dose of the mRNA-1273 Vaccine among Cancer Patients
By Christopher Dukes, Jeffrey E. Lancet, Barbara J. Kuter, Marine Potez| MDPI@ All articles published by MDPI are made immediately available worldwide under an open access license. No specialpermission is required to reuse all or part of the article published by MDPI, including figures and tables. Forarticles published under an open access Creative Common CC BY license, any part of the article may be reused withoutpermission provided that the original article is clearly cited. For more information, please refer tohttps://www.mdpi.com/openaccess.
Company Info
Leukemia
The Leukemia & Lymphoma Society (LLS) is a leading organization dedicated to fighting blood cancers, including leukemia, lymphoma, Hodgkin's disease, and myeloma. Founded in 1949 and headquartered in the United States, LLS operates regional offices across North America. Its mission focuses on curing these diseases and enhancing the quality of life for patients and their families. LLS provides a wide range of services, including funding for blood cancer research, which totals nearly $1.8 billion. The organization offers free information, education, and personalized support to help patients navigate their treatment options. Additionally, LLS advocates for policies that increase research funding and improve access to therapies. It also provides educational resources and financial assistance to help patients manage the costs associated with cancer treatment. Through its efforts, LLS significantly impacts the lives of patients and families affected by blood cancers.
Tampa, United States
+1 914-949-5213
Founded: 1949